Introduction
Acute myeloid leukemia (AML) is a group of hematologic neoplasms with diverse genetic abnormalities.
1-3 Risk stratification based on cytogenetic characteristics divides AML patients into three subgroups, favorable, intermediate, and unfavorable risk cytogenetics 4 , with 5-year overall survival of 55%, 38%, 11% respectively. 5 The cytogenetically normal AML (CN-AML)
of the intermediate-risk group, which accounts for about half of total AML, is also heterogeneous as shown by inferior prognosis in cases with FLT3-ITD or DNMT3A mutations, and good prognosis in cases with NPM1 mutations or bi-allelic CEBPA mutations in the absence of FLT3-ITD mutations. 4, 6 In addition, mutations in other genes, such as IDH1, IDH2, ASXL1, WT1 and TET2, have been identified in this group recently. 7 Because of the heterogenetic nature, many genetic mutations identified so far have yet to demonstrate their ability to confidently predict the outcome for the CN-AML patients.
Previous studies have revealed that the glucose metabolism, including glycolysis and TCA cycle, is reprogrammed in many malignancies as shown by the accelerated glycolysis to provide energy/biosynthetic precursors and by the active truncated TCA cycle to produce intermediates for tumor cells. 8, 9 The altered glucose metabolism is closely associated with the therapeutic resistance and clinical outcome. [9] [10] [11] High expression and increased activity of lactate dehydrogenase-A in glycolysis induce Taxol resistance in breast cancer cells. 12 Overexpression of pyruvate dehydrogenase kinase-3 in colon cancer contributes to hypoxia-induced drug resistance. 10 Total lesion glycolysis is associated with the survival of lung adenocarcinoma patients. 13 An intermediate metabolite of TCA cycle, 2-hydroxyglutarate (2-HG, consisting of both D-and L-hydroxyglutarate enantiomers), generated by mutated isocitrate dehydrogenases 1 and 2 (IDH1/2), is considered as an "onco-metabolite" and identified to be a prognostic factor of For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From AML in a recent report published by our group. 14 Based on these reports, we tested a hypothesis in this study that the glucose metabolism might be modified in AML patients and be associated with the prognosis of the patients.
Mass spectrometry-based metabolomic profiling is sensitive and robust, allowing for simultaneous identification of a large number of metabolites 15 and their changes associated with a pathophysiological process. The past few years have witnessed successful applications of this technology in the study of various cancers. 16, 17 Here, we present a gas chromatography-time-offlight mass spectrometry (GC-TOFMS)-based metabolomics study of AML serum, which is focused on the glucose metabolism and a panel of serum metabolite markers instead of 2-HG alone, with potential for AML risk stratification. 4 The treatment protocols were provided in supplementary appendix.
Serum samples were collected from patients at diagnosis using the same protocol among all the hematology centers. Overnight fasting peripheral blood samples were collected in the morning and transferred into vacuum blood collection tubes without any anticoagulants. All blood samples were clotted at room temperature for less than 2 hours, and centrifuged at 956 × g for 10 minutes. Serum samples were obtained and stored at -80 °C until analysis.
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Metabolomic profiling with GC-TOFMS
Metabolomic profiles of all serum samples were achieved using GC-TOFMS platform as previously described. 16, 17 Samples were randomized prior to GC-TOFMS analysis to decrease experimental drifts. Quality control (QC) samples, which were prepared by mixing equal amounts of serum samples from all enrolled subjects, were used to control intra-and inter-batch variability. QC samples were distributed evenly among the injections for each day. Detailed descriptions of sample preparation and GC-TOFMS analysis methods were provided in supplementary appendix.
After the pre-treatment of baseline correction, de-noising, smoothing, alignment, timewindow splitting, and multivariate curve resolution, raw data containing retention time, intensity, and m/z of each peak were obtained. A total of 100 metabolites were identified by the comparison with the internal library built with the standard reference compounds and the NIST library (Wiley registry). The intensity data of these metabolites were used to perform metabolomics profiling analysis. Six metabolites of the glucose metabolism differentially expressed in AML serum, including glycerol-3-phosphate, pyruvate, lactate, citrate, 2-oxoglutarate, and 2-HG, were quantitatively determined from the calibration curves.
Gene-expression profiling
Human U133 Plus 2.0 GeneChip (Affymetrix, Santa Clara, CA, US) was used for geneexpression profiling. Briefly, the RNA was extracted by using RNeasy micro kit (Qiagen, GmBH, 44.71 ± 1.66) and the ratio of GAPDH 3' to 5' (mean ± SD: 2.12 ± 0.91).
Quantitative RT-PCR
The expression of metabolic genes, including glycolysis and TCA cycle, was measured by quantitative RT-PCR (q-PCR). 18S rRNA was used as the internal control. The assay was performed using SYBR ® Premix Ex Taq TM (Takara, Otsu, Japan) on an Applied Biosystems 7900 Real Time PCR machine (Applied Biosystems, Foster city, CA, US). All primers were listed in Table S1 . 
Cell viability assay

Development of prognosis-risk score
As stated in the INTRODUCTION section, we focused on the glucose metabolism in this study to screen potential metabolite biomarkers for AML risk stratification. Among the total metabolites identified in glucose metabolism, 6 of them were differentially expressed in AML serum. This panel of metabolites was selected for prognostic value assessment. The log2 transformed and then z-score normalized quantitative data of these metabolites were used in the analysis.
Clinical outcome was analyzed in CN-AML patients due to the relatively low heterogeneity in this group as compared to the other cytogenetic groups. Among 263 patients in this group, only 233 cases with detailed therapeutic information were enrolled for prognostic analysis. A predictive principal component analysis (PCA) model was fitted in the training matrix (n = 134) only containing the above panel of 6 metabolite biomarkers. The PCA model was used to generate prognosis-risk score (PRS) for each patient in training set and to predict PRS for each case in validation set (n = 99). Specifically, the first principal component (a weighted average For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From expression among those 6 metabolites) was applied to obtain PRS for each patient, as it accounted for the largest variability in the data. The median PRS in the training set was used as the cut-off value to divide the two sets of patients into two groups: those with low and high PRSs.
Data treatment and statistical analysis
The metabolomic data was normalized using internal standard L-2-chlorophenylalanine, and intra-batch and inter-batch calibration was achieved using QC samples (see supplementary methods for details). Multivariate statistical model of orthogonal partial least square discriminate analysis (OPLS-DA) was constructed with the software SIMCA-P+ (version 11.0, Umetric, Umea, Sweden). Wilcoxon rank-sum test with Bonferroni correction was performed to identify differentially expressed metabolites. Altered metabolic pathways in AML were analyzed by means of the quantitative enrichment analysis (QEA) algorithm represented in metabolite set enrichment analysis (MSEA) method. 19 Visualization of metabolic pathways was achieved by using metscape 2 running on cytoscape.
20,21
The clinical characteristics, molecular features, and outcomes were compared between CN-AML with low and high PRSs. For prognosis analysis, complete remission (CR) was defined as previously described. 22 Overall survival (OS) was measure as time from disease diagnosis to death from any cause, or censoring for patients alive at the time of their final follow-up. Eventfree survival (EFS) was defined as time from disease diagnosis until removal from study because of failure to achieve CR, relapse, or death from any cause. OS and EFS were compared between low and high PRS groups by means of Kaplan-Meier method followed with log-rank test.
Multivariate Cox regression analysis was applied to evaluate the prognostic value of PRS after 
Results
Metabolic alteration and distinct glucose metabolism of acute myeloid leukemia
We used the samples from the hematology center of Rui Jin Hospital as the training set and the samples from 6 hematology centers as the validation set. There were no significant differences in age, gender, serum alanine aminotransferase (ALT) or creatinine between the two sample sets, or between HC and AML patients in each set (Table 1) . A total of 100 metabolites were identified in this study (Table S2 ). The metabolomic profile of the AML group represented by these 100 metabolites was distinct from that of the HC ( Figure 1A A total of 10 metabolites involved in the glucose metabolism were identified in this study, including glucose, glycerol-3-phosphate, pyruvate, and lactate in glycolysis, and citrate, 2-oxoglutarate, succinate, fumarate, malate and 2-HG in TCA cycle. Six of them were differentially expressed in AML serum in both training and validation sets (Bonferroni-corrected P < 0.05, FDR q < 0.05, Figure 1E ). Among these 6 metabolites, glycerol-3-phosphate, lactate, and citrate were decreased, while pyruvate, 2-oxoglutarate, and 2-HG were increased in AML serum as compared to HC ( Figure 1E and Table S3 ).
In the remaining 90 metabolites, 41 of them were significantly modified in AML serum in both training and validation sets (Bonferroni-corrected P < 0.05, FDR q < 0.05, Figure S1A ).
The total of 47 modified metabolites included alcohols, amino acids, carbohydrates, fatty acids, Therefore, we chose this panel of 6 metabolites in glucose metabolism to assess prognostic potential ( Table 2 ).
The prognostic value of the panel of those metabolites was first evaluated in CN-AML patients. The estimated 2-year overall survival (OS) and event-free survival (EFS) rates for these 233 patients were 38.20% (95% CI: 31.60%-46.20%) and 31.70% (95% CI: 25.50%-39.40%), respectively. There were no significant differences between training (n = 134) and validation (n = 99) sets for clinical characteristics, gene mutations, complete remission (CR) rate, median OS, and median EFS (Table S4) . A predictive PCA model was fitted in the training set, including above 6 metabolite markers (Table 2) . Meanwhile, each of the metabolites was evaluated in association with the survival of patients using the importance scores computed by SuperPC algorithm. 24 Lactate, 2-oxoglutarate, pyruvate, 2-HG and glycerol-3-phosphate were found to be negatively associated with the OS and EFS of patients, while citrate was positively associated ( Table 2 ). As described in METHODS section, patients in two sets were divided into low and high PRS groups based on
the PRS values from PCA model. There were no significant differences in clinical characteristics and molecular features between these two groups (Table S4 ).
In the training set, patients with low PRS achieved a shorter median OS and median EFS (352 days and 299 days respectively) than those with high PRS (716 days and 559 days respectively) (P = 0.03 for OS and P = 0.02 for EFS; Figure 2 and Table S4 ). The estimated 2-year OS rates were 31.70% vs. 49.10%, and the estimated 2-year EFS rates were 21.30% vs.
41.50% between these two groups (Table S4) . A similar pattern was observed in the validation set, those with low PRS showing worse median OS and EFS (293 days and 146 days respectively) than those with high PRS (1093 days and 1093 days, respectively) (P = 0.009 for OS and P = 0.01 for EFS; Figure 2 and Table S4 ). The estimated 2-year OS rates were 21.20% vs. 61.90%, and the estimated 2-year EFS rates were 0% vs. 56.00% for the two groups (Table S4 ).
Univariate analysis demonstrated that low PRS, age, WBC count, percentage of bone marrow (BM) blasts, FLT3-ITD mutations, DNMT3A mutations, and high 2-HG were poor-risk factors, while CEBPA bi-allelic mutations was favorable factor for OS and EFS (Table S5) (Table S7) .
Verification of the modified glucose metabolism of CN-AML with low PRS by geneexpression profiling
The regression weights of metabolite biomarkers in the predictive PCA model (Table 2) indicated that lactate, 2-oxoglutarate, pyruvate, 2-HG and glycerol-3-phosphate were negatively correlated to PRS value, while citrate was positively correlated. Correspondingly, lactate, 2-oxoglutarate, pyruvate, 2-HG, and glycerol-3-phosphate were increased in the low PRS group, while citrate was reduced ( Figure 3A ). These analyses suggested glycolysis and a truncated TCA cycle were both enhanced in low PRS group. Accordingly, gene-expression profiling in bone marrow blasts from 7 patients with low PRS and 4 patients with high PRS verified the modified glucose metabolism of patients with low PRS, as demonstrated by the up-regulated glycolytic genes ALDOB/LDHA and TCA cycle genes CS/IDHG/SDHB/MDH2 in this group (P < 0.05; Figure 3B ).
Aberrant glycolysis pathway as potential therapeutic target for AML
To uncover the biological role of the modified glucose metabolism in patients with low PRS, 5 AML cell lines, HL-60, U937, OCI-AML3, THP-1 and KG-1 were chosen for investigation of their metabolic features. As compared with HL-60, the expression of glycolytic genes and TCA cycle genes was increased in the other 4 cell lines ( Figure 4A ), indicating glycolysis and TCA cycle were both enhanced in these 4 cell lines.
In view of the fact that the HK1, a gene key to glycolysis pathway, showed significant variation in above the 5 cell lines (P = 1. 25 × 10 -8 ; Figure 4A ), we tried two glycolytic inhibitors, 2-DG and DCA, to treat these cells. The proliferations of all 5 cell lines were inhibited in a dosedependent manner under the separate treatment of 2-DG and DCA ( Figure 4B and 4C) . Next we evaluated the effect of glycolysis on drug sensitivity. We first explored the association between glycolysis and the sensitivity to Ara-C, a common drug used in AML chemotherapy. Enhanced glycolysis was associated with decreased sensitivity as demonstrated by the higher IC50 (median inhibition concentration) values of Ara-C for U937, OCI-AML3, THP-1, and KG-1 cells harboring increased glycolysis as compared to HL-60 harboring relatively low level of glycolysis (P < 0.05; Figure S6A ). We down-regulated the expression of HK1 in U937 and OCI-AML3 using the shRNA technology, and observed significantly increased Ara-C sensitivity for these two cell lines ( Figure 4D and 4E) . The results demonstrated that enhanced glycolysis in leukemic cells contributed to decreased Ara-C sensitivity. Thus we used 2-DG and Ara-C together to treat AML cell lines. Synergistic effect was observed between these two drugs for all 5 AML cell lines ( Figure 4F-4I and Table S8 ), demonstrating that inhibiting glycolysis potentiated the cytotoxicity induced by Ara-C in AML cells.
It was notable that AML primary blast cells from de novo patients presenting distinct glycolysis were all sensitive to glycolytic inhibition as shown by the marked dose-dependent inhibition on the proliferation of these cells by 2-DG or DCA treatment ( Figure S6B , Figure 4J and 4K). The use of 2-DG also potentiated cytotoxicity of Ara-C in AML primary cells ( Figure   4L -4N, Table S8 ). In addition, 2-DG showed reduced cytotoxicity in healthy monocytes, as demonstrated by the higher IC50 value for healthy monocytes as compared to the AML primary For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From cells (P = 0.004, Figure S6C ). No synergism was observed between 2-DG and Ara-C for healthy monocytes (Table S8) .
Discussion
AML has been studied thoroughly at the facets of epigenomic and genomic sequencing, gene transcription, and protein expression patterns. 6, 25, 26 However, a comprehensive metabolic signature for this group of diseases is still lacking. Hence, we carried out a serum metabolomic study for newly diagnosed AML patients, and showed that 47 metabolites were differentially expressed and 45 metabolic pathways were altered. Enhanced glycolysis was observed in AML, as previously reported in many tumors. In cancer cells, the mitochondrion converts its original role as simply a "power house" to a new role as a biosynthetic hub, where more intermediates and anabolic precursors are produced through carboxylation of pyruvate and glutaminolysis, to support cell proliferation, an activity known as anaplerosis. 27, 28 Increased serum levels of pyruvate and 2-oxoglutarate in AML patients suggested an anaplerotic activity in leukemic cells Metabolic pathway analysis suggested that glycine/serine/threonine metabolism ( Figure S3A) and methionine/cysteine metabolism ( Figure S3B ) were accelerated to increase the pyruvate production, which is in need for mitochondrial respiration and proliferation. 29 Free fatty acids, the intermediates in synthesis of unsaturated fatty acids, were all down-regulated in AML serum ( Figure S1A and S4) , indicating increased consumption of fatty acids for lipids synthesis by
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A panel of 6 serum metabolites involved in glucose metabolism has independent prognostic value in CN-AML patients. Low PRS from the PCA model fitted by these 6 metabolites predicted poor OS and EFS independent of other prognostic markers. In addition, our data suggested that metabolic signature was a unique feature of AML independent of cytogenetics risk since there was no significant metabolic difference among distinct cytogenetics risk groups.
As mentioned above, low PRS was linked to enhanced glycolysis and TCA cycle. Compared to HL-60 cells, U937, OCI-AML3, THP-1, and KG-1 cells showed significantly increased glycolysis and TCA cycle. Enhanced glycolysis in these leukemic cells contributed to reduced sensitivity to Ara-C. In the present work, we found that inhibition of the glycolysis activity suppressed the proliferation of AML cell lines and primary AML cells. Moreover, glycolytic inhibitor 2-DG synergized with Ara-C to enhance its cytotoxic effects on both cell lines as well as primary blast cells. Taken together, our results show that a panel of serum metabolite markers, indicative of glucose metabolism activity, can predict the AML patients with relatively good or poor prognosis. The study also suggests that glucose metabolism, especially the glycolysis pathway, may be a potential target for AML therapy, and that a combination of glycolytic inhibitor and chemotherapeutic agent may be a novel strategy for AML treatment. For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From
